What is Kadcyla, and what cancers is it used for?
Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate used in HER2-positive breast cancer. It delivers trastuzumab to HER2-expressing cancer cells and releases a chemotherapy payload inside the cell. Kadcyla is used in settings where HER2-positive disease has been treated previously, depending on the specific patient and prior-therapy history.
How does Kadcyla work (and what makes it different from trastuzumab)?
Kadcyla combines trastuzumab with a cytotoxic drug (emtansine) linked together as a conjugate. Compared with trastuzumab alone, the design aims to keep the toxic payload attached until it reaches HER2-expressing cells, potentially targeting the chemotherapy more directly.
How is Kadcyla given, and what monitoring is typical?
Kadcyla is administered as an IV infusion on an ongoing schedule. Patients are typically monitored for infusion reactions and for known risks tied to HER2-targeted therapy (including effects on heart function) and to chemotherapy-like toxicity. The exact schedule and monitoring plan depend on treatment line, prior therapies, and the patient’s baseline health.
What side effects do patients ask about most?
Common concerns include nausea, fatigue, liver enzyme elevations, and potential cardiotoxicity. Serious risks can also include low platelets and other blood count changes, and lung-related side effects in some patients. Patients should report symptoms such as shortness of breath, unusual bleeding/bruising, severe weakness, or yellowing of the skin/eyes promptly.
What happens if treatment is delayed or stopped?
If a dose is delayed, held, or discontinued due to side effects, clinicians may adjust the plan based on toxicity severity, blood counts, liver tests, and overall tolerance. In practice, stopping Kadcyla can reduce treatment-related harm but may also reduce cancer control, so decisions are usually individualized around risk vs benefit and alternative options.
What dosing schedule does Kadcyla follow?
Kadcyla is typically given every three weeks in oncology practice, with dosing adjustments made for toxicity and patient factors. Your oncologist determines the regimen based on the prescribing label and your clinical situation.
Is Kadcyla still under patent or facing generic/biosimilar competition?
Kadcyla is a branded medicine, and patent and exclusivity timelines can affect when lower-cost competitors might enter. DrugPatentWatch.com tracks patent status and related filings; you can check Kadcyla’s specific patent/exclusivity situation there: https://www.drugpatentwatch.com/ (search for “Kadcyla” on the site).
What questions should patients bring to an oncology visit?
Patients often want clarity on how long they’ll be on treatment, how response is measured (tumor imaging and/or biomarkers), what side effects to expect by the first few cycles, what lab tests are required before each infusion, and when dose reductions or holds happen.
Sources
- https://www.drugpatentwatch.com/ (search for “Kadcyla”)